caris life sciences inc. - CAI

CAI

Close Chg Chg %
34.81 -0.29 -0.83%

Open Market

34.52

-0.29 (0.83%)

Volume: 9.68K

Last Updated:

Sep 9, 2025, 9:47 AM EDT

Company Overview: caris life sciences inc. - CAI

CAI Key Data

Open

$34.81

Day Range

34.50 - 34.91

52 Week Range

N/A - N/A

Market Cap

$9.80B

Shares Outstanding

281.22M

Public Float

92.71M

Beta

N/A

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$3.09

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

739.30K

 

CAI Performance

1 Week
 
-9.33%
 
1 Month
 
17.01%
 
3 Months
 
N/A
 
1 Year
 
N/A
 
5 Years
 
N/A
 

CAI Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 9
Full Ratings ➔

About caris life sciences inc. - CAI

Caris Life Sciences, Inc. provides diagnostics and anatomic pathology services. It develops an unbiased profiling platform for novel target identification, drug development and delivery, diagnostic and disease monitoring, and precision medicine enabling aspects. It offers services throughout the U.S., Europe, Australia and other international markets. The company was founded by David D. Halbert in 2008 and is headquartered in Irving, TX.

CAI At a Glance

Caris Life Sciences, Inc.
750 West John Carpenter Freeway
Irving, Texas 75039
Phone 1-866-771-8946 Revenue 412.26M
Industry Packaged Software Net Income -281,890,000.00
Sector Technology Services 2024 Sales Growth 34.669%
Fiscal Year-end 12 / 2025 Employees N/A
View SEC Filings

CAI Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio N/A
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA N/A
Enterprise Value to Sales N/A
Total Debt to Enterprise Value N/A

CAI Efficiency

Revenue/Employee N/A
Income Per Employee N/A
Receivables Turnover 4.672
Total Asset Turnover 1.09

CAI Liquidity

Current Ratio 1.277
Quick Ratio 1.038
Cash Ratio 0.409

CAI Profitability

Gross Margin 43.366
Operating Margin -62.369
Pretax Margin -68.377
Net Margin -68.377
Return on Assets -74.512
Return on Equity N/A
Return on Total Capital -191.668
Return on Invested Capital -207.458

CAI Capital Structure

Total Debt to Total Equity N/A
Total Debt to Total Capital 288.47
Total Debt to Total Assets 123.427
Long-Term Debt to Equity N/A
Long-Term Debt to Total Capital 243.479
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Caris Life Sciences Inc. - CAI

Collapse All in section
All values USD millions. 2023 2024 5-year trend
Sales/Revenue
- - 306.13M 412.26M
-
Sales Growth
- - - +34.67%
-
Cost of Goods Sold (COGS) incl D&A
- - 216.82M 233.48M
-
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
- - 49.00M 48.91M
-
Depreciation
- - 49.00M 48.91M
-
Amortization of Intangibles
- - - -
-
COGS Growth
- - - +7.68%
-
Gross Income
- - 89.31M 178.78M
-
Gross Income Growth
- - - +100.18%
-
Gross Profit Margin
- - +29.17% +43.37%
-
2023 2024 5-year trend
SG&A Expense
- - 408.86M 435.90M
-
Research & Development
- - 116.88M 113.92M
-
Other SG&A
- - 291.98M 321.99M
-
SGA Growth
- - - +6.61%
-
Other Operating Expense
- - - -
-
Unusual Expense
- - (179.00K) (18.48M)
-
EBIT after Unusual Expense
- - (319.37M) (238.64M)
-
Non Operating Income/Expense
- - 9.57M 6.77M
-
Non-Operating Interest Income
- - 11.26M 7.12M
-
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - 31.61M 50.02M
-
Interest Expense Growth
- - - +58.26%
-
Gross Interest Expense
- - 31.61M 50.02M
-
Interest Capitalized
- - - -
-
Pretax Income
- - (341.42M) (281.89M)
-
Pretax Income Growth
- - - +17.43%
-
Pretax Margin
- - -111.53% -68.38%
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
- - (341.42M) (281.89M)
-
Minority Interest Expense
- - - -
-
Net Income
- - (341.42M) (281.89M)
-
Net Income Growth
- - - +17.43%
-
Net Margin Growth
- - -111.53% -68.38%
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
- - (341.42M) (281.89M)
-
Preferred Dividends
- - 121.11M 96.37M
-
Net Income Available to Common
- - (462.53M) (378.26M)
-
EPS (Basic)
- - -1.6455 -1.3457
-
EPS (Basic) Growth
- - - +18.22%
-
Basic Shares Outstanding
- - 281.09M 281.09M
-
EPS (Diluted)
- - -1.6455 -1.3457
-
EPS (Diluted) Growth
- - - +18.22%
-
Diluted Shares Outstanding
- - 281.09M 281.09M
-
EBITDA
- - (270.55M) (208.21M)
-
EBITDA Growth
- - - +23.04%
-
EBITDA Margin
- - -88.38% -50.50%
-

Snapshot

Average Recommendation BUY Average Target Price 39.125
Number of Ratings 9 Current Quarters Estimate -0.174
FY Report Date 09 / 2025 Current Year's Estimate -2.494
Last Quarter’s Earnings -7.97 Median PE on CY Estimate N/A
Year Ago Earnings N/A Next Fiscal Year Estimate 0.298
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 8 8 9 9
Mean Estimate -0.17 -0.03 -2.49 0.30
High Estimates -0.02 0.08 -0.56 0.49
Low Estimate -0.51 -0.34 -8.86 -0.05
Coefficient of Variance -116.65 -448.03 -105.86 59.28

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 9 9
OVERWEIGHT 0 0
HOLD 0 0
UNDERWEIGHT 0 0
SELL 0 0
MEAN Buy Buy

Caris Life Sciences Inc. in the News